Research Article

Delayed $^{18}$F-FDG PET/CT Appearance of Urachal Adenocarcinomas

Lian Xu, Yiping Shi, Yining Wang, Xiang Zhou, Gan Huang, Ruohua Chen, and Jianjun Liu

Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Correspondence should be addressed to Jianjun Liu; liujijrj@sina.com

Lian Xu, Yiping Shi, and Yining Wang contributed equally to this work.

Received 26 April 2020; Revised 5 July 2020; Accepted 28 August 2020; Published 14 September 2020

Academic Editor: Barbara Salvatore

Copyright © 2020 Lian Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Urachal carcinoma is a rare urological malignancy. Use of $^{18}$F-FDG PET/CT in urological oncology has developed slowly because of the urinary elimination of $^{18}$F-FDG. We investigated whether delayed postdiuretic $^{18}$F-FDG PET/CT could be used for diagnosing urachal carcinoma. Methods. This retrospective study included 6 patients who underwent delayed postdiuretic $^{18}$F-FDG PET/CT for the evaluation of urachal carcinoma. The delayed postdiuretic PET/CT parameters and clinical characteristics of urachal carcinoma were investigated. Results. There was no significant difference in the SUV max between the primary tumors and the urine in the bladder before delayed diuresis (25.4 ± 19.5 vs. 42.9 ± 31.1, $P = 0.18$). However, the SUV max of the primary tumors was significantly higher than the SUV max of urine after delayed diuresis (25.4 ± 19.5 vs. 3.5 ± 1.6, $P = 0.002$). Diuretic $^{18}$F-FDG PET/CT was positive in all patients when compared with normal liver tissues or urine after delayed diuresis. The SUV max, TLR, and TUR of the primary tumors were 25.4 (range: 7.2–58.9), 7.0 (range: 1.8–14.7), and 6.8 (range: 3.8–11.3), respectively. Delayed postdiuretic $^{18}$F-FDG PET/CT had a negative predictive value of 100% (5/5) for predicting lymph node metastasis. One patient received chemotherapy after radical resection of urachal carcinoma because $^{18}$F-FDG PET/CT found lung metastases, and one patient only received chemotherapy because PET/CT found peritoneal and skeletal metastases. Conclusions. Delayed postdiuretic $^{18}$F-FDG PET/CT is a useful tool for the preoperative evaluation of urachal carcinoma. $^{18}$F-FDG PET/CT may improve clinical decision making and management of urachal carcinomas.

1. Introduction

Urachal carcinoma is a rare urological malignancy accounting for only 0.34% of all bladder neoplasms, which extends from the bladder dome to the umbilicus [1, 2]. The most common histologic type of urachal carcinoma is adenocarcinomas. Computed tomography and magnetic resonance imaging are the commonly used imaging modalities for the diagnosis of urachal carcinoma [2, 3]. $^{18}$F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has become a useful modality in cancer evaluation based on hypermetabolism observed in malignant cells [4]. However, use of $^{18}$F-FDG PET/CT, specifically in urological oncology, has developed relatively slowly because the radiotracer is excreted into the urine and bladder, making structures and original tumors difficult to see against the tracer background [5, 6]. It is encouraging to note that $^{18}$F-FDG PET/CT has been used in the diagnosis of bladder cancer through delayed postdiuretic imaging and has exhibited high sensitivity and accuracy in our recent studies [7, 8]. However, because of the rarity of urachal carcinoma, the $^{18}$F-FDG PET/CT literature consists only of case reports [9]. In this study, we describe the delayed $^{18}$F-FDG PET/CT findings in urachal adenocarcinomas, which, to our knowledge, is the first series to assess the diagnostic value of delayed $^{18}$F-FDG PET/CT for urachal carcinomas.

2. Methods

2.1. Patients. We retrospectively reviewed all available clinicopathological data for 6 patients with urachal carcinoma who were examined by delayed postdiuretic $^{18}$F-FDG PET/CT and, subsequently, histologically diagnosed by
radical resection of urachal carcinoma (n = 5) or biopsy (n = 1) at the Shanghai Jiaotong University-affiliated Ren Ji Hospital from January 2017 to July 2019. Among the 6 patients, 5 patients were treated with radical resection of urachal carcinoma; the remaining one patient was treated with chemotherapy. The study was approved by the institutional review board of the Shanghai Jiaotong University-affiliated Ren Ji Hospital and was in accordance with the 2013 revision of the Declaration of Helsinki. The need for informed consent was waived in this study.

2.2. Delayed Postdiuretic 18F-FDG PET/CT Imaging. Blood glucose levels were measured and found to be less than 140 mg/dL at the time the 18F-FDG was administered. All patients received an intravenous 3.7 MBq/kg injection of 18F-FDG after fasting for at least 6 h and resting for 1 h. 18F-FDG PET/CT scanning from the groin to the skull base was performed using a whole-body scanner (Biograph mCT; Siemens, Erlangen, Germany) (early PET/CT imaging). After early PET/CT imaging, delayed postdiuretic PET/CT imaging was performed after 120 min of early PET/CT imaging. Patients received 20 mg of furosemide by the oral route and an extra oral intake of at least 500 mL water. Patients were asked to void frequently to reduce the urine physiological uptake of the radiotracer 18F-FDG. Delayed imaging covered a range of one or two bed positions centered at the location of the bladder. PET images were attenuation-corrected and anatomically correlated with low-dose CT images.

For quantitative analysis, irregular regions of interest were placed over the most intense area of 18F-FDG uptake on delayed postdiuretic PET/CT imaging. The SUVmax was calculated as (maximum pixel value with the decay-corrected region-of-interest activity [MBq/mL]/injected dose [MBq]/body weight [kg]). The PET/CT images were evaluated by two experienced nuclear medicine physicians. The TLR was calculated as the SUVmax of primary tumors/SUVmax of the liver. The TUR was calculated as the SUVmax of primary tumors/SUVmax of urine (delay).

2.3. Statistical Analysis. The data are presented as mean ± SD. Statistically significant differences between groups were compared using the Mann–Whitney U-test. P < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS, version 13.0 (SPSS Inc.).

3. Results

3.1. Patient Characteristics. The patient characteristics and delayed 18F-FDG PET/CT finding are listed in Table 1. There were 3 males and 3 females with an average age of 48.7 (range 35–71 years). The tumor size averaged 4.3 cm in the largest cross-sectional diameter (range 2.8–7.8 cm). Five cases appeared as solid lesions and one case appeared as mixed cystic-solid lesion. Four cases appeared as a round-like nodule or mass and two cases appeared as irregular lumps. All were adenocarcinomas. Calcifications were radiologically visible in one case. One case (Case 2) had distant metastasis in the peritoneal and bone. In our series, 5 patients (83.3%) presented with hematuria as the first clinical sign, and 1 patient (16.7%) presented with painful pelvic mass as the first clinical sign.

3.2. PET Appearance. The mean SUVmax of urine in the bladder of the early image was 42.9 (range 13.5–91.6), so the SUVmax of lesion cannot be easily detected due to urine interference, especially for the intraluminal portion. On the image of 18F-FDG PET/CT in the delayed phase, the bladder is distended and the SUVmax of urine was very low (mean, 3.5; range 1.8–5.2). So, the lesion can be easily visualized by axial CT and PET, particularly the intraluminal portion of the mass. Diuretic 18F-FDG PET/CT was positive in all patients when compared with normal liver tissues or urine after delayed diuresis. The SUVmax of primary tumors before diuresis was 23.6 (range 6.8–60.1). The SUVmax after diuresis, TLR, and TUR of the primary tumors were 25.4 (range 7.2–58.9), 7.0 (range 1.8–14.7), and 6.8 (range 3.8–11.3), respectively. The SUVmax of the primary tumors was significantly higher than the SUVmax of urine after delayed diuresis (25.4 ± 19.5 vs. 3.5 ± 1.6, P = 0.002). However, there was no significant difference in the SUVmax between the primary tumors and the urine before delayed diuresis (25.4 ± 19.5 vs 42.9 ± 31.1, P = 0.18). Representative images of a patient (Case 3) with urachal carcinoma who underwent 18F-FDG PET/CT scanning (early PET/CT imaging) and delayed postdiuretic PET/CT scanning are shown in Figure 1.

Of the 6 patients, 2 patients underwent ultrasound examination, 1 patient underwent computed tomography, and 3 patients underwent MRI. Though they all found the primary tumors, they did not find any metastatic lesion. Of the 6 patients, 4 patients underwent radical resection of urachal carcinoma because PET/CT found no lymph node and distant metastasis. Postoperative pathology further confirmed the 18F-FDG PET/CT results. One patient (Case 1) received chemotherapy after radical resection of urachal carcinoma and 18F-FDG PET/CT found lung metastases, though 18F-FDG PET/CT and postoperative pathology both found no lymph node metastasis. Thus, 18F-FDG PET/CT had a negative predictive value of 100% (5/5) for predicting lymph node metastasis. One patient (Case 2) only received chemotherapy because PET/CT found peritoneal and skeletal metastases.

4. Discussion

18F-FDG PET/CT has been widely used for diagnosis of various malignant tumors [10–12]. Unfortunately, 18F-FDG is not an ideal radiotracer for use in urology because of its urinary elimination [13]. In this study, the potential of delayed postdiuretic 18F-FDG PET/CT for diagnosing urachal carcinoma was analyzed. To the best of our knowledge, this was the first study to assess the diagnostic value of delayed 18F-FDG PET/CT in urachal carcinomas. Though Yang et al. reported a case of urachal carcinoma detected by 18F-FDG PET/CT, it consists of only one case and delayed postdiuretic 18F-FDG PET/CT was unattempted [9]. So, the SUVmax of urachal carcinoma cannot be easily detected due to urine interference in this case. Several
| Case | Gender | Age | SUVmax of the lesion | SUVmax of urine (early) | SUVmax of urine (delay) | SUVmax of the liver | History | Conventional Imaging methods | Size (mm) | Morphology and density | Metastasis | Treatment       |
|------|--------|-----|----------------------|------------------------|------------------------|---------------------|----------|-----------------------------|----------|----------------------|------------|----------------|----------|
| 1    | Female | 35  | 18.9                 | 13.5                   | 2.6                    | 2.3                 | Hematuria| Ultrasound                 | 40       | Round-like mass, solid | Lung       | Surgery and chemotherapy |
| 2    | Male   | 52  | 38.2                 | 91.6                   | 5.1                    | 3.6                 | Hematuria| Ultrasound                 | 78       | Irregular lumps, solid  | Peritoneal, skeletal | Chemotherapy |
| 3    | Male   | 44  | 58.9                 | 51                     | 5.2                    | 4                   | Hematuria| MR                         | 30       | Tubercle like, solid    | None       | Surgery         |
| 4    | Female | 71  | 16.8                 | 63.2                   | 4.4                    | 4.2                 | Pelvic mass| MR                         | 50       | Irregular lumps, cystic-solid | None       | Surgery         |
| 5    | Male   | 52  | 12.3                 | 19.4                   | 1.8                    | 4.2                 | Hematuria| CT                         | 28       | Round tubercle like, solid | None       | Surgery         |
| 6    | Female | 38  | 7.2                  | 18.9                   | 1.8                    | 4                   | Hematuria| MR                         | 30       | Tubercle like, solid    | None       | Surgery         |
investigators have considered $^{18}$F-FDG PET/CT of no utility in the detection of localized urological malignancies and lymph nodes [14]. The limitation of $^{18}$F-FDG PET/CT has been attributed to the urinary excretion of $^{18}$F-FDG. The pooled activity in the urinary system makes the evaluation of urinary lesions difficult. Catheterization has been proposed to reduce bladder spillover for the evaluation of the pelvic region in several studies. In addition to catheterization, our previous studies showed that washing out the excreted $^{18}$F-FDG could also overcome this limitation in bladder cancer [7, 8]. Delayed postdiuretic $^{18}$F-FDG PET/CT exhibited high sensitivity and accuracy for diagnosing bladder cancer in these studies [7, 8]. In this study, we showed that the lesion of urachal carcinoma can be easily visualized by delayed postdiuretic $^{18}$F-FDG PET/CT and the lesion was positive in all patients when compared with normal liver tissues or urine after delayed diuresis.

CT and MRI have been used to assess the local extent of urachal carcinomas and the presence of pelvic and visceral metastases [15]. However, they have limitations because they can detect only lymph nodes and distant metastasis that are quite enlarged. CT fails to detect lymph node involvement in up to 40–70% of patients with lymph node metastases [16]. $^{18}$F-FDG PET/CT was, however, more sensitive than conventional CT scan in detecting lymph node metastases based on hypermetabolism of lymph node involvement [17]. In this study, 2 patients underwent ultrasound examination, 1 patient underwent computed tomography, and 3 patients underwent MRI. Though they all found the primary tumors, they did not find any metastatic lesion. $^{18}$F-FDG PET/CT found no lymph node metastasis in 5 cases, and postoperative pathology further confirmed the accuracy. Thus, delayed postdiuretic $^{18}$F-FDG PET/CT had a negative predictive value of 100% (5/5) for predicting lymph node metastasis in our study. In one patient, radical resection of urachal carcinoma was not performed because PET/CT found peritoneal and skeletal metastases. Thus, delayed postdiuretic $^{18}$F-FDG PET/CT have the potential to improve clinical decision making and management of urachal carcinomas.

Our study was, in part, limited by its retrospective design and small sample size. Although delayed postdiuretic $^{18}$F-FDG PET/CT may have a good diagnostic performance for urachal carcinoma, further large and prospective studies were needed to confirm our results.

5. Conclusions

Our results were the first to show the diagnostic value of delayed postdiuretic $^{18}$F-FDG PET/CT in the urachal carcinomas. These results may advance the development of noninvasive strategies to improve clinical decision making and management of urachal carcinomas. Further larger and prospective studies that include more clinical samples are needed to confirm the value and efficacy of delayed postdiuretic $^{18}$F-FDG PET/CT in urachal carcinomas.

Abbreviations

$^{18}$F-FDG: $^{18}$F-fluorodeoxyglucose positron emission PET;
SUVmax: The maximum of standardized uptake value.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the principles of the institutional review board of Shanghai Jiao Tong University-affiliated Ren ji Hospital and the 1975 Declaration of Helsinki, as revised in 2013. This article does not contain any studies with animals performed by any of the authors.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
LJJ and CRH designed the experiments. XL, WYN, ZX, and HG performed data collection and the statistical analysis. CRH and SYP wrote the manuscript and replied to the reviews. Lian Xu, Yiping Shi, and Yining Wang contributed equally to this work. All authors approved the final draft of this manuscript.

Acknowledgments
This work was supported by grants from the National Natural Science Foundation of China (nos. 81701724, 81771858, 81830052, 81530053, 81602415, 81571710, 81771861, 81601520, 81601536, and 81572719) and Innovative research team of high-level local universities in Shanghai.

References
[1] S. H. Brick, A. C. Friedman, H. M. Pollack et al., “Urachal carcinoma: CT findings,” Radiology, vol. 169, no. 2, pp. 377–381, 1988.
[2] C. M. Fishman, P. J. Woodward, and B. J. Wagner, “Computed tomographic appearance of urachal adenocarcinoma: review of 25 cases,” European Radiology, vol. 15, no. 1, pp. 79–84, 2005.
[3] V. Monteiro and T. M. Cunha, “Urachal carcinoma: imaging findings,” Acta Radiologica Short Reports, vol. 1, 2012.
[4] C. Plathow and W. A. Weber, “Tumor cell metabolism imaging,” Journal of Nuclear Medicine, vol. 49, no. Suppl_2, pp. 43S–63S, 2008.
[5] K. Kitajima, S. Yamamoto, K. Fukushima, R. Hohenfellner, “Update on advances in molecular PET in urological oncology,” Japanese Journal of Radiology, vol. 34, no. 7, pp. 470–485, 2016.
[6] S. Mafeld, N. Vasdev, A. Patel et al., “Evolving role of positron emission tomography (PET) in urological malignancy,” BJU International, vol. 116, no. 4, pp. 538–545, 2015.
[7] R. Ali, X. Zhou, J. Liu, and G. Huang, “Relationship between the expression of PD-1/PD-L1 and 18FDG uptake in bladder cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 46, no. 4, pp. 848–854, 2019.
[8] H. Yan, X. Zhou, X. Wang et al., “Delayed (18) F FDG PET/CT imaging in the assessment of residual tumors after transurethral resection of bladder cancer,” Radiology, vol. 2019, Article ID 190032, 2019.
[9] G. Yang, Z. Wang, S. Liu, F. Wu, and D. Li, “A rare case of urachal carcinoma metastatic to thoracic vertebra detected by FDG PET/CT,” Clinical Nuclear Medicine, vol. 42, no. 7, pp. 544–546, 2017.
[10] X. Zhou, R. Chen, W. Xie, Y. Ni, J. Liu, and G. Huang, “Relationship between 18FDG accumulation and lactate dehydrogenase A expression in lung adenocarcinomas,” Journal of Nuclear Medicine, vol. 55, no. 11, pp. 1766–1771, 2014.
[11] R. Chen, Y. Wang, X. Zhou, G. Huang, and J. Liu, “Preoperative PET/CT (18) F-FDG standardized uptake by lymph nodes as a significant prognostic factor in patients with colorectal cancer,” Contrast Media & Molecular Imaging, vol. 2018, Article ID 5802109, 2018.
[12] C. Wu, R. Chen, X. Zhou, Q. Xia, and J. Liu, “Preoperative evaluation of residual tumor in patients with endometrial carcinoma by using 18F-FDG PET/CT,” Journal of Cancer, vol. 11, no. 8, pp. 2283–2288, 2020.
[13] A. Razik, C. J. Das, and S. Sharma, “PET-CT and PET-MR in urological cancers other than prostate cancer: an update on state of the art,” Indian Journal of Urology, vol. 34, pp. 20–27, 2018.
[14] H. Schöder and S. M. Larson, “Positron emission tomography for prostate, bladder, and renal cancer,” Seminars in Nuclear Medicine, vol. 34, no. 4, pp. 274–292, 2004.
[15] G. E. Voges, E. Tauschke, M. Stöckle, P. Alken, and R. Hohenfellner, “Computerized tomography: an unreliable method for accurate staging of bladder tumors in patients who are candidates for radical cystectomy,” Journal of Urology, vol. 142, no. 4, pp. 972–974, 1989.
[16] M. L. Paik, M. J. Scolieri, S. L. Brown, J. P. Spirnak, and M. I. Resnick, “Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy,” The Journal of Urology, vol. 163, pp. 1693–1696, 2000.
[17] B. Nayak, P. N. Dogra, N. Naswa, and R. Kumar, “Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, no. 3, pp. 386–393, 2013.